METHODS AND SYSTEMS USING INTEGRATED METABOLOMICS AND PHARMACOKINETICS FOR MULTI-COMPONENT DRUG EVALUATION

• US 20140024132A1
• Filed: 03/14/2011
• Published: 01/23/2014
• Est. Priority Date: 03/12/2010
• Status: Abandoned Application

• Current Assignee: University of North Carolina At Greensboro (University of North Carolina System)
• Original Assignee: University of North Carolina At Greensboro (University of North Carolina System)
• Inventors: Jia, Wei, Qiu, Yunping
• Application Number:
  US13/634,133
• Publication Number:
  US 20140024132A1
• Time in Patent Office: Days
• US Class Current: 436/173
• CPC Class Codes: G01N 27/62 by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Disclosed are methods and systems for identifying biochemical changes in a subject in response to administration of a multi-component therapeutic and one or more active ingredients in the multi-component therapeutic. The methods and systems of the invention may be used to elucidate the interaction of the biological system'"'"'s genome with its environments, and in the pharmacokinetic, pharmacodynamic and toxicology analysis of multi-component therapeutics. The metabolomics methods and systems of the invention can also be used in studies of plant derived agents to demonstrate biochemical alterations in response to the dynamic multi-component intervention.

Claims

1. A method of identifying biochemical changes in a subject in response to administration of a multi-component therapeutic and one or more active ingredients in the multi-component therapeutic comprising:

(a) determining a component profile for the multi-component therapeutic,

(b) determining a pre-administration metabolome in a subject sample before administration of the multi-component therapeutic;

(c) determining a post-administration metabolome in a subject sample after administration of the multi-component therapeutic;

(d) comparing the component profile for the multi-component therapeutic to the subject'"'"'s post-administration metabolome, wherein shared components are absorbed components from the multi-component therapeutic by the subject;

(e) comparing the subject'"'"'s pre-administration metabolome to the subject'"'"'s post-administration metabolome, wherein shared components are altered endogenous components that are differentially expressed by administration of the multi-component therapeutic;

wherein components in the subject'"'"'s post-administration metabolome that are not absorbed components or altered endogenous components are metabolized and/or biotransformed components; and

wherein the absorbed components, metabolized and/or biotransformed components and the altered endogenous components are used to characterize the biochemical changes in the subject in response to active ingredients in the multi-component therapeutic

2. The method of claim 1, wherein the altered endogenous components and the metabolized and/or biotransformed components comprise biochemical changes in the subject in response to administration of the multi-component therapeutic, and the absorbed components comprise components in the multi-component therapeutic that are involved in the biochemical changes in the subject in response to administration of the multi-component therapeutic.

6. The method of claim 1, wherein the sample from the subject comprises a biofluid or a tissue.

7. The method of claim 6, wherein the biofluid is serum, plasma, urine, saliva.

8. The method of claim 1, wherein the multi-component therapeutic component profile and the subject'"'"'s pre-administration and post-administration metabolomes determined using chromatographic and spectrometric analytical techniques.

9. The method of claim 8, wherein the chromatographic and spectrometric analytical techniques comprise gas chromatography and/or liquid chromatography coupled with mass spectrometry (MS) and/or nuclear magnetic resonance (NMR).

10. The method of claim 1, wherein comparison of the multi-component therapeutic component profile and the subject'"'"'s post-administration metabolome and comparison of the subject'"'"'s pre-administration and post-administration metabolomes comprises multivariate and/or univariate statistical analysis.

11. The method of claim 10, wherein the univariate statistical analysis comprises Student'"'"'s T-test univariate statistical analysis.

12. The method of claim 9, wherein the shared components are identified using join properties.

13. The method of claim 11, wherein the join properties comprise one or more of retention time, accurate compound mass, fragmentation pattern and chemical shift.

14. The method of claim 10, wherein the multivariate statistical analysis comprises Pearson product-moment correlation coefficient analysis, wherein pair-wise metabolite vectors are compared at one or more time points before and/or after administration of the multi-component therapeutic to identify linear correlations between the absorbed components, the altered endogenous metabolites and the metabolized and/or biotransformed components.

15. The method of claim 14, wherein the pair-wise metabolite vectors comprise one or more of an absorbed component vs. an altered endogenous metabolite, and a metabolized and/or biotransformed component vs. an altered endogenous component.

16. The method of claim 15, wherein metabolite vectors are also derived using the mean value of a metabolite at more than one time point before and/or after administration of the multi-component therapeutic.

17. The method of claim 1, wherein the multi-component therapeutic is administered to the subject over time and/or at varying dosages to identify time-dependent and/or dosage-dependent biochemical changes in the subject'"'"'s post-administration metabolome in response to administration of the multi-component therapeutic.

18. The method of claim 14, wherein the linear correlations identified between the altered endogenous metabolites and the metabolized and/or biotransformed components are used to conduct pharmacodynamic and/or toxicology studies to characterize the biochemical changes in the subject in response to administration of the multi-component therapeutic.

19. The method of claim 18, wherein the pharmacodynamic and/or toxicology studies can be used to assess efficacy of a treatment with the multi-component therapeutic, to predict probable side effects that may be associated with treatment with the multi-component therapeutic, and/or to determine optimal dosages and treatment schedules for treatment with the multi-component therapeutic for diseases involving the altered endogenous metabolites.

20. The method of claim 14, wherein the linear correlations identified between the absorbed components, the altered endogenous metabolites and the metabolized and/or biotransformed components are used to conduct pharmacokinetic studies to characterize the biochemical changes in the subject in response to the one or more active ingredients in the multi-component therapeutic.

21. The method of claim 20, wherein the pharmacokinetic studies can be used to assess efficacy of a treatment with the multi-component therapeutic, to predict probable side effects that may be associated with treatment with the multi-component therapeutic, and/or to determine optimal dosages and treatment schedules for treatment with the multi-component therapeutic for diseases involving the altered endogenous metabolites.

22. The method of claim 1, wherein the absorbed components, the altered endogenous metabolites and the metabolized and/or biotransformed components comprise one or more compounds selected from the compounds listed in Tables 1-5.

3-5. -5. (canceled)

23. A system to identifying biochemical changes in a subject in response to administration of a multi-component therapeutic and one or more active ingredients in the multi-component therapeutic comprising:

(a) a part for determining a component profile for the multi-component therapeutic, a pre-administration metabolome in a subject sample before administration of the multi-component therapeutic, and a post-administration metabolome in a subject sample after administration of the multi-component therapeutic;

(b) a part for comparing the component profile for the multi-component therapeutic, the pre-administration metabolome in a subject sample before administration of the multi-component therapeutic, and the post-administration metabolome in a subject sample after administration of the multi-component therapeutic;

wherein comparison of results in identification of absorbed components, the altered endogenous metabolites and the metabolized and/or biotransformed components; and

(c) a part for analyzing correlations between the absorbed components, the altered endogenous metabolites and the metabolized and/or biotransformed components,

wherein correlations between the absorbed components, the metabolized and/or biotransformed components and the altered endogenous components are used to characterize the biochemical changes in the subject in response to active ingredients in the multi-component therapeutic

24-44. -44. (canceled)